Indeed, numerous ongoing clinical trials are investigating the efficacy of ICIs targeting LAG-3 and TIM-3 in various cancer types including head and neck cancer (e.g., NCT04811027, NCT05287113), especially in combination with PD-1 antibodies. Here, PDCD1 is linked to cancer.